Categories: Life Science
The Global Eczema Therapeutics Market size is estimated to reach $6.2 billion by 2026, growing at a CAGR of 7.2% over the forecast period of 2021-2026.
Global Eczema Therapeutics Market Overview
Eczema has been one of the predominant skin conditions one can develop over a while. Moreover, if one's skin itches from time to time and forms a red-colored patch over their hand, they probably have eczema. Eczema is commonly termed atopic dermatitis; wherein, atopic refers to allergy.
Furthermore, all eczemas portray common symptoms, such as dry or scaly skin, redness, or itching, which may persist. Moreover, allergy plays a quintessential role in flaring cases of atopic dermatitis. Food allergies have been linked to the flaring up of such dermatitis. Most common foods include milk, egg, and soy.
Additionally, when the body's immune system malfunctions owing to asthma, it becomes a major cause of eczema. Moreover, there are a lot of skin irritants around one person, for example, harsh detergents or soaps or perfumes.
Factors such as increased government spending and support for research activities and the rich pipeline of therapeutic products have been the key drivers for the Eczema Therapeutics Industry in the projected 2022-2027.
Impact of COVID-19:
There has been a small backlog in revenue of Eczema Therapeutics owing to the COVID-19 pandemic. As a result, patients were forced to stay at home and avoid any kind of appointment, especially during initial lockdowns. This has resulted in a significant drop in revenue for the market.
Key Takeaways from Global Eczema Therapeutics Market Report:
Environmental triggers about eczema have been a key driver for market growth.
Researchers have concluded that environmental changes are impacting the occurrence of eczema in patients. Moreover, researchers have found a strong correlation between eczema and asthma, as both are linked to inflammation.
The vice versa also holds true, as half of the people with moderate or severe eczema will also have asthma, allergic rhinitis, and food allergies. In addition, inheriting a filaggrin gene mutation from your parents can lead to a "leaky" skin barrier that reduces your skin's ability to block allergens and allows moisture to escape. This causes eczema symptoms like dry and irritated skin.
Allergens, such as pollen, dander, and dust mites, contain enzymes that may also break down the skin's barrier. According to Environmental Protection Agency, warmer temperatures could increase the unhealthy air and water pollutants, which triggers asthma and atopic dermatitis. Additionally, around 10% of the US population, or 31.6 million people in the US, have atopic dermatitis.
Therapeutics-related after-effects or side-effects are the significant market growth barrier.
In 2017, US FDA approved dupilumab to treat people suffering from acute dermatitis; moreover, the therapy was approved instead of being used when other treatments had failed, such as oral and injectable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes.
Specific side effects were noticed, such as local site injection, conjunctivitis, headaches, and nasopharyngitis. Furthermore, hormonal imbalances were seen through which one observed alopecia areata. Further, medications such as immunosuppressive are often recommended, which increase one's risk of developing cancer and other severe viral or bacterial infections.
By treatment, the market for the biologics segment to grow at the highest CAGR during the forecast period.
During the forecast period, the biologics segment is predicted to develop at the fastest rate of XX%. A biologic is a drug made from living organism cells such as humans-animals-plants or fungi. They modify the biological reaction if given in the right amount.
Monoclonal antibodies are now being aggressively used across the globe to treat such conditions. Biologic mAb needs to be injected to be effective since taking them through the digestive system. However, it would disrupt their three-dimensional protein structure and render them unable to bind to their targets, much like an essential need to be a specific configuration to open a lock.
Medication held a dominant market share in the year 2020. Medications predominantly involved the usage of corticosteroids, antibiotics, and other emollients and moisturizers. The first line of defense to control eczema is to start with a mild corticosteroid, and often the following medication works in a patient with non-severe dermatitis.
Moreover, steroids can be given in topical formats and grouped in four forms -> mild, moderate, potent, and very potent. As the name suggests, the concentration would widely vary with age and disease prognosis. For example, hydrocortisone 1% is often used, especially when treating children.
By Distribution Channel, Eczema Therapeutics Market for Online to grow at the highest CAGR during the forecast period
The Online segment is estimated to be the fastest-growing during the projection period, with a CAGR of XX%. It is owing to the new strategies of discounts, cashback, and membership being excessively advertised. Further, the MRP of MOMOZ Cream from Torrent Pharmaceutical is close to INR 182; however, one can avail of the said medicine at INR 132 by availing Tata 1 Mg Care Plan. Hence, the market is positively poised due to the heavy price differential.
The offline segment held a dominant market share in the year 2020. It is due to the medication being prescribed by the doctor, such as steroids. And the availability of such drugs in doctors or hospital pharmacies. Additionally, allergies that lead to atopic dermatitis are unpredictable, making the following segment lucrative.
North America to account for the largest market share during the forecast period.
North America held the largest share of the Eczema Therapeutics Market in 2020, with a global market share of 32%. It is due to an overall prevalence of the disease across the region, supplemented with increasing biopharma companies' research and development activities. As per CDC, 10.1% of the US Population or close to 36 million have had eczema, which roughly translates to one in ten individuals.
The Asia Pacific is also set to be the fastest-growing over 2021-2026. It is owing to the rising inclination to create better medical infrastructure and the growing avenues of start-ups to provide seed money for better research pertaining activities that will allow the market region to grow.
Key Market Players
Key Players in the Global Eczema Therapeutics Market consist of Union Therapeutics are Incyte, Pfizer, Abbvie, Lilly, Leo, Aclaris Theraputics, Reistone Biopharma, Cara Therapeutics, Asana Biosciences, among others.
Report Coverage and Scope
The report "Global Eczema Therapeutics Market" by Research Informatic covers an in-depth detailed analysis for the following segment, covered under the scope.
By Route of Administration
By Distribution Channel
Global Eczema Therapeutics Market Growth, Trend and Forecast 2021-2028
Chapter 1 Eczema Therapeutics Market Overview
1.1 Product Overview and Scope of Eczema Therapeutics
1.2 Eczema Therapeutics Market Segmentation by Type
1.2.1 Global Production Market Share of Eczema Therapeutics by Type in 2020
1.2.1 Type 1
1.2.2 Type 2
1.2.3 Type 3
1.3 Eczema Therapeutics Market Segmentation by Application
1.3.1 Eczema Therapeutics Consumption Market Share by Application in 2020
1.3.2 Application 1
1.3.3 Application 2
1.3.4 Application 3
1.4 Eczema Therapeutics Market Segmentation by Regions
1.4.1 North America
1.4.4 Southeast Asia
1.5 Global Market Size (Value) of Eczema Therapeutics (2014-2028)
Chapter 2 Global Economic Impact on Eczema Therapeutics Industry
2.1 Global Macroeconomic Environment Analysis
2.1.1 Global Macroeconomic Analysis
2.1.2 Global Macroeconomic Environment Development Trend
2.2 Global Macroeconomic Environment Analysis by Regions
Chapter 3 Global Eczema Therapeutics Market Competition by Manufacturers
3.1 Global Eczema Therapeutics Production and Share by Manufacturers (2020 and 2020)
3.2 Global Eczema Therapeutics Revenue and Share by Manufacturers (2020 and 2020)
3.3 Global Eczema Therapeutics Average Price by Manufacturers (2020 and 2020)
3.4 Manufacturers Eczema Therapeutics Manufacturing Base Distribution, Production Area and Product Type
3.5 Eczema Therapeutics Market Competitive Situation and Trends
3.5.1 Eczema Therapeutics Market Concentration Rate
3.5.2 Eczema Therapeutics Market Share of Top 3 and Top 5 Manufacturers
3.5.3 Mergers & Acquisitions, Expansion
Chapter 4 Global Eczema Therapeutics Production, Revenue (Value) by Region (2014-2021)
4.1 Global Eczema Therapeutics Production by Region (2014-2021)
4.2 Global Eczema Therapeutics Production Market Share by Region (2014-2021)
4.3 Global Eczema Therapeutics Revenue (Value) and Market Share by Region (2014-2021)
4.4 Global Eczema Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.5 North America Eczema Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.6 Europe Eczema Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.7 China Eczema Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.8 Japan Eczema Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.9 Southeast Asia Eczema Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.10 India Eczema Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
Chapter 5 Global Eczema Therapeutics Supply (Production), Consumption, Export, Import by Regions (2014-2021)
5.1 Global Eczema Therapeutics Consumption by Regions (2014-2021)
5.2 North America Eczema Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.3 Europe Eczema Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.4 China Eczema Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.5 Japan Eczema Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.6 Southeast Asia Eczema Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.7 India Eczema Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
Chapter 6 Global Eczema Therapeutics Production, Revenue (Value), Price Trend by Type
6.1 Global Eczema Therapeutics Production and Market Share by Type (2014-2021)
6.2 Global Eczema Therapeutics Revenue and Market Share by Type (2014-2021)
6.3 Global Eczema Therapeutics Price by Type (2014-2021)
6.4 Global Eczema Therapeutics Production Growth by Type (2014-2021)
Chapter 7 Global Eczema Therapeutics Market Analysis by Application
7.1 Global Eczema Therapeutics Consumption and Market Share by Application (2014-2021)
7.2 Global Eczema Therapeutics Consumption Growth Rate by Application (2014-2021)
7.3 Market Drivers and Opportunities
7.3.1 Potential Applications
7.3.2 Emerging Markets/Countries
Chapter 8 Eczema Therapeutics Manufacturing Cost Analysis
8.1 Eczema Therapeutics Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Eczema Therapeutics
Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Eczema Therapeutics Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Eczema Therapeutics Major Manufacturers in 2020
9.4 Downstream Buyers
Chapter 10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
Chapter 11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change
Chapter 12 Global Eczema Therapeutics Market Forecast (2021-2028)
12.1 Global Eczema Therapeutics Production, Revenue Forecast (2021-2028)
12.2 Global Eczema Therapeutics Production, Consumption Forecast by Regions (2021-2028)
12.3 Global Eczema Therapeutics Production Forecast by Type (2021-2028)
12.4 Global Eczema Therapeutics Consumption Forecast by Application (2021-2028)
12.5 Eczema Therapeutics Price Forecast (2021-2028)
Chapter 13 Appendix
The Global Eczema Therapeutics Market market size is estimated to reach $6.2 billion by 2026, growing at a CAGR of 7.2% over the forecast period of 2021-2026.
Environmental triggers pertaining to eczema have been a key driver for market growth. Researchers have arrived at a conclusion that environmental changes are impacting the occurrence of eczema in patients. Moreover, researchers have found a strong correlation between eczema and asthma, as both are linked to inflammation.
Incyte, Pfizer, Abbvie, Lilly, Leo, Aclaris Theraputics, Reistone Biopharma, Cara Therapeutics, Asana Biosciences, among others.
North America held the largest share of the Eczema Therapeutics Market market in 2020, with a global market share of 32%. It is owing to a wide prevalence of the disease across the region-supplemented with increasing research and development activities carried on by the biopharma companies.
The market has been segmented By Type (Atopic Dermatitis, Contact Dermatitis), By Treatment (Medication, Self-Care, Biologics), By Route of Administration (Topical, Oral, Injectable), By Distribution Channel (Offline, Online), Region (North America, Europe, Asia-Pacific, Middle East & Africa, and South America)
Published On:Jan 2021
Historical Data:2017 - 2019
No of Pages:250